Company Presentation
Bad Homburg, November 2022
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Company Presentation November 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 2 |
- Company overview
- Business update Q3/22
- Financials Q3/22 & Outlook
- #FutureFresenius
Company Overview 02 03 04 05
Fresenius is at the heart of healthcare
Company Presentation November 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 4 |
Company Overview 02 03 04 05
A Global Leader in Healthcare Products and Services
in sales (FY/2021)
€ 37.5 bn
Global presence in 100+
countries
Leading market
#1 positions
Long-term opportunities in growing, non-cyclicalmarkets
100 +
Employees
worldwide
(as of June 30, 2022)
300,000+
Strong financial performance and cash flow generation
Company Presentation November 2022 © Fresenius SE & Co. KGaA Investor Relations & Sustainability | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 17 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2022 09:08:01 UTC.